Share this article
Share this article
LONDON, Jan. 27, 2021 /PRNewswire/ - ADVANZ PHARMA Corp. Limited ( ADVANZ PHARMA or the Company ), a specialty pharmaceutical company with a strategic focus on complex medicines in Europe, today announced that its board of directors has reached an agreement on the terms of a cash offer, to be made by a subsidiary ( Bidco ) of Nordic Capital, pursuant to which Nordic Capital will acquire the entire issued and to-be-issued limited voting share capital of ADVANZ PHARMA (the Acquisition ). This offer highlights the value that our employees around the world have collectively contributed towards building ADVANZ PHARMA into the strong and diverse company it is today, said Graeme Duncan, Chief Executive Officer of ADVANZ PHARMA. In addition, this Acquisition will significantly help the business through both the capital support, and Nordic Capital s deep sector expertise. I am very much looking forward to working with Nordic Capital to deliver o